Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
News for Incyte Genomics Inc (Nasdaq: INCY), operating as Incyte Corporation, centers on its activities as a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. Company releases describe a portfolio of first‑in‑class medicines and a pipeline of proprietary therapeutics, making INCY news particularly relevant for investors and healthcare observers following cancer and immune‑related drug development.
Recent headlines highlight late-stage clinical trial results and regulatory milestones. Incyte has reported positive topline data from the Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R‑CHOP as first‑line therapy for diffuse large B‑cell lymphoma, meeting primary and key secondary endpoints. Other news covers European Commission and Japanese approvals of Minjuvi in combination regimens for relapsed or refractory follicular lymphoma and DLBCL, underscoring the company’s role in B‑cell lymphoma treatment.
In immuno‑oncology, Incyte Biosciences Japan G.K. has announced approval of Zynyz (retifanlimab) with platinum‑based chemotherapy as first‑line treatment for advanced squamous cell carcinoma of the anal canal, following earlier U.S. approval in a similar setting. Additional coverage describes submissions to European regulators and the broader POD1UM clinical program evaluating retifanlimab across solid tumors.
News flow also features pipeline updates for INCA033989, a first‑in‑class mutCALR‑targeted monoclonal antibody for myeloproliferative neoplasms. Incyte has disclosed Breakthrough Therapy designation from the U.S. FDA for essential thrombocythemia with Type 1 CALR mutations, along with Phase 1 data in ET and myelofibrosis showing hematologic responses, spleen volume reductions, symptom improvements and safety findings.
Beyond R&D, Incyte issues releases on leadership changes, board transitions, inducement equity grants and participation in major healthcare investor conferences. For investors and analysts, the INCY news page provides a centralized view of clinical, regulatory, corporate governance and capital markets developments affecting the company.
Incyte (Nasdaq:INCY) reported positive 54-week Phase 3 STOP-HS results for povorcitinib in adults with moderate to severe hidradenitis suppurativa (HS). Key efficacy: up to 71.4% HiSCR50, 57% HiSCR75, 29% HiSCR100 and 16.1–20.2% full lesion clearance (ANdT=0). Durable QoL gains and lesion reductions persisted through Week 54. Safety through 54 weeks was consistent with prior data; TEAEs occurred in 76.2–83.4%, serious TEAEs were 3.7–6.4%. NDA and MAA for HS are under review.
Incyte (NASDAQ:INCY) announced executive leadership appointments to support strategic focus and long-term growth. Pablo J. Cagnoni, M.D., becomes President, Incyte and Global Head of Research and Development; Steven Stein, M.D., is named EVP, Chief Medical Officer and Head of Late-stage Development; Mohamed Issa, Pharm.D., is named EVP and Head of U.S. Commercial.
The company said U.S. Oncology and U.S. Immunology will be integrated into a single U.S. commercial organization to align launch execution and operations. Matteo Trotta, EVP and General Manager, U.S. Dermatology, will leave following a transition period.
Incyte (Nasdaq:INCY) announced it will present late-breaking 54-week data for povorcitinib in hidradenitis suppurativa from the Phase 3 STOP-HS1 and STOP-HS2 trials at the AAD Annual Meeting, March 27–31, 2026, in Denver. Multiple ePosters will feature ruxolitinib cream across atopic dermatitis and vitiligo.
The company said the 54-week results provide longer-term evidence on safety and efficacy and reinforce growth potential for its Inflammation and Autoimmunity franchise. Presentations include a late-breaking oral session on March 28, 2026.
Incyte (Nasdaq: INCY) announced European Commission approval of Zynyz (retifanlimab) plus carboplatin and paclitaxel for first-line treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).
The decision follows a CHMP positive opinion and Phase 3 POD1UM-303 results showing a 37% reduction in risk of progression or death (P=0.0006) and median PFS of 9.3 vs 7.4 months. No new safety signals were identified; serious adverse reactions occurred in 47% of combination patients.
Eli Lilly (NYSE: LLY) announced a positive CHMP opinion recommending Olumiant (baricitinib) for adolescents ages 12 to <18 with severe alopecia areata. The recommendation is based on Phase 3 BRAVE-AA-PEDS results showing 42.4% achieved ≥80% scalp hair coverage at 36 weeks (4 mg).
The opinion moves to the European Commission for final action, expected in one to two months; a U.S. decision is expected in the second half of 2026.
Incyte (Nasdaq: INCY) will present at three investor conferences in early March 2026: TD Cowen on March 2 at 10:30 am EST, Leerink Partners on March 10 at 9:20 am EDT, and Barclays on March 11 at 8:30 am EDT.
Each presentation will be webcast live at Investor.Incyte.com and replays will be available for 30 days.
Incyte (Nasdaq:INCY) reported Q4 2025 total revenue $1.51B (+28% Y/Y) and FY2025 total revenue $5.14B (+21% Y/Y). FY2025 total net product revenue was $4.35B (+20%), above guidance. Cash and marketable securities rose to $3.6B. Company provided FY2026 net product revenue guidance of $4.77–$4.94B and GAAP R&D+SG&A expense guidance of $3.495–$3.675B.
Incyte (Nasdaq:INCY) announced a positive CHMP opinion recommending approval of Zynyz (retifanlimab) plus carboplatin and paclitaxel for first-line treatment of adult metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC) in Europe, pending European Commission decision.
Phase 3 POD1UM-303/InterAACT2 showed a 37% reduction in risk of progression or death (P=0.0006); median PFS 9.3 vs 7.4 months. No new safety signals; serious adverse reactions occurred in 47% of patients.
Incyte (Nasdaq:INCY) scheduled its fourth quarter and year-end 2025 financial results release and conference call for Tuesday, February 10, 2026. The press release will be issued at 7:00 a.m. ET, followed by a conference call and webcast with slides at 8:00 a.m. ET.
Domestic dial-in: 877-407-3042. International dial-in: 201-389-0864. Conference ID: 13758313. A replay of the call will be available for 30 days (U.S. replay 877-660-6853; international 201-612-7415). The live webcast and slides will be accessible at Investor.Incyte.com and available for replay for 90 days.
Incyte (NASDAQ:INCY) reported positive topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) plus lenalidomide with R-CHOP versus R-CHOP alone as first-line treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL).
The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p=0.019) and met the key secondary endpoint of event-free survival (EFS). No new safety signals were observed. Incyte plans to file a sBLA in H1 2026 and will submit frontMIND data for presentation at an upcoming scientific meeting.